Addressing breast cancer treatment injustices entails overcoming social barriers and empowering patients for unrestricted healthcare decisions.
Transparency, patient education, and regulatory oversight are essential for improving the FDA's accelerated drug approval program, especially for cancer drugs.
it can be the alternative for people who do not want to perform the coloscopy — is being designed for people who have no symptoms of colon cancer and don’t belong to the high-risk group. as reported by HealthDay.